Glioblastoma therapy in the elderly: One age does not fit all

The Lancet Oncology

Volumn 13, Issue 9, 2012, Pages 857-858

  Nghiemphu, Phioanh Leia ^a   Cloughesy, Timothy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE; TEMOZOLOMIDE;

AGED; ASTROCYTOMA; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; COMORBIDITY; DECISION MAKING; FUNCTIONAL STATUS; GERIATRIC PATIENT; GLIOBLASTOMA; HEALTH CARE ACCESS; HUMAN; LETTER; LIFE EXPECTANCY; LIFESPAN; PRIORITY JOURNAL; PROGNOSIS; PROVOCATION; QUALITY OF LIFE;

BRAIN NEOPLASMS; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; MALE;

EID: 84865548432     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70368-6     Document Type: Letter

References (5)

1. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2008 (March 23, 2012 Revision) Central Brain Tumor Registry of the United States, (accessed July 10, 2012). http://www.cbtrus.org/2012-NPCR-SEER/CBTRUS_Report_2004-2008_3-23-2012.pdf.
2. Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL Epidemiology of brain tumors. Neurol Clin 2007, 25:867-890. vii.
3. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
4. Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy for patients aged older than 60 years with glioblastoma: the Nordic randomised phase 3 trial. Lancet Oncol 2012, for the Nordic Clinical Brain Tumour Study Group (NCBTSG), published online Aug 7. http://dx.doi.org/10.1016/S1470-2045(12)70265-6.
5. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012, 13:707-715.